Soleno Therapeutics Inc (SLNO) — Cash Flow-to-Debt Ratio
Soleno Therapeutics Inc (SLNO) has a Cash Flow-to-Debt Ratio of 0.23x as of March 2026, meaning its operating cash flow of $25.98 Million could theoretically repay 0% of its total liabilities ($112.59 Million) in one year. Explore SLNO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Soleno Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Soleno Therapeutics Inc across 14 annual periods. Also explore SLNO total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Soleno Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Soleno Therapeutics Inc. For market capitalisation and broader financial context, see SLNO market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.41x | $46.80 Million | $113.72 Million | ▲ +151.1% |
| 2024 | -0.80x | $-69.10 Million | $85.86 Million | ▲ +25.2% |
| 2023 | -1.08x | $-24.94 Million | $23.18 Million | ▲ +16.4% |
| 2022 | -1.29x | $-20.78 Million | $16.15 Million | ▲ +17.7% |
| 2021 | -1.56x | $-27.77 Million | $17.76 Million | ▼ -20.5% |
| 2020 | -1.30x | $-25.22 Million | $19.43 Million | ▼ -73.5% |
| 2019 | -0.75x | $-17.38 Million | $23.23 Million | ▲ +18.4% |
| 2018 | -0.92x | $-11.68 Million | $12.74 Million | ▼ -15.1% |
| 2017 | -0.80x | $-9.95 Million | $12.49 Million | ▲ +87.4% |
| 2016 | -6.34x | $-13.50 Million | $2.13 Million | ▼ -206.3% |
| 2015 | -2.07x | $-10.30 Million | $4.98 Million | ▼ -764.2% |
| 2014 | -0.24x | $-4.48 Million | $18.73 Million | ▼ -967.1% |
| 2013 | -0.02x | $-885.22K | $39.45 Million | ▲ +76.4% |
| 2012 | -0.10x | $-3.50 Million | $36.71 Million | — |